Core Viewpoint - The article discusses the strategic shift of Yaoshi Bang, a leading digital comprehensive service platform in the outpatient pharmaceutical industry, which has proposed the "Upward Move" strategy to enhance product offerings, deepen brand partnerships, and develop proprietary brands, aiming for resilient growth amidst a challenging market environment [2][7][15]. Group 1: Industry Overview - In 2024, the A-share pharmaceutical industry is projected to achieve a total revenue of 2.42 trillion yuan, marking a 1.0% year-on-year decline, the first decrease in recent years [2]. - The net profit attributable to shareholders is expected to be 140.4 billion yuan, reflecting a significant decline of nearly 12%, indicating the first negative growth in five years [2]. - The domestic pharmaceutical market has entered a phase of stock competition, with stricter medical insurance cost control and centralized procurement becoming the norm, leading to increased demands for supply chain integration capabilities [2][10]. Group 2: Company Performance - Yaoshi Bang achieved a revenue of 17.904 billion yuan in 2024, representing a year-on-year growth of 5.5%, with net profit turning positive for the first time at 30.01 million yuan, and adjusted net profit reaching 1.57 billion yuan, up 20.1% [8][11]. - The operating cash flow remained positive at 656 million yuan, showing a 45% year-on-year increase, indicating robust growth across economic cycles [8]. Group 3: Strategic Initiatives - The "Upward Move" strategy focuses on three dimensions: enriching product offerings, deepening brand collaborations, and building proprietary brands, which collectively enhance supply chain capabilities and operational service levels [2][9][15]. - Yaoshi Bang has established a comprehensive marketing system, covering 491,000 pharmacies and 330,000 grassroots medical institutions, achieving a monthly active buyer count of 433,000, showcasing strong market penetration [10][11]. - The company has expanded its exclusive strategic cooperation brands and proprietary brand products to over 830 SKUs, with a transaction scale of 651 million yuan, reflecting a 152% year-on-year growth [11][13]. Group 4: Market Trends - The total number of pharmacies in China reached 700,881 by Q4 2024, with a year-on-year growth of 2.3%, but a quarter-on-quarter decline of 0.5%, indicating a trend of increasing store closures [4]. - The retail terminal pharmaceutical sales scale is projected to reach 574 billion yuan in 2024, with a growth rate of 3.7%, while sales of health products and medical devices have seen significant declines of 24.8% and 20%, respectively [5][10].

Industry Overview - In 2024, the A-share pharmaceutical industry is projected to achieve a total revenue of 2.42 trillion yuan, marking a 1.0% year-on-year decline, the first decrease in recent years [1] - The net profit attributable to shareholders is expected to be 140.4 billion yuan, representing a significant year-on-year drop of nearly 12%, the first negative growth in five years [1] - The domestic pharmaceutical market has entered a phase of stock competition, with stricter medical insurance cost control and centralized procurement becoming the norm [1][2] Company Strategy - As a leading digital comprehensive service platform in the outpatient pharmaceutical industry, the company has launched the "Upward Move" strategy in 2023, focusing on enriching products, deepening brand cooperation, and building proprietary brands [1][3] - The company achieved a revenue of 17.904 billion yuan in 2024, a year-on-year increase of 5.5%, and its net profit turned positive for the first time, reaching 30.01 million yuan [3][4] - The company has covered 491,000 pharmacies and 330,000 grassroots medical institutions, penetrating 98.9% of county-level areas and 91.2% of townships, showcasing its extensive channel advantages [4] Market Dynamics - The number of retail pharmacies in China has reached a turning point, with a total of 700,881 pharmacies as of Q4 2024, reflecting a year-on-year growth of 2.3% but a quarter-on-quarter decline of 0.5% [2] - The closure rate of pharmacies in 2024 is approximately 5.76%, up from 3.8% in 2023, indicating an accelerating trend of store closures [2] - The retail terminal drug sales scale is expected to reach 574 billion yuan in 2024, with a year-on-year growth of 3.7%, while drug sales growth is at 2.3% [2] Product Development - The company has expanded its exclusive strategic cooperation brands and proprietary brand products to over 830 SKUs in 2024, with a transaction scale of 651 million yuan, a year-on-year increase of approximately 152% [6] - The proprietary brand "Le Yaoshi" has over 250 varieties and has achieved significant market penetration, with annual sales exceeding 38 million yuan for a key product [6][7] - The self-operated business has seen a compound annual growth rate of 78% from 2021 to 2023, with the annual GMV increasing from 83 million yuan to 263 million yuan [7] Consumer Behavior - In the stock economy era, the price-performance ratio has become the primary factor influencing consumer behavior, reflecting a shift towards more rational and cautious purchasing decisions [8] - The pharmaceutical consumption market, perceived as a necessity, is also showing signs of fatigue as consumer income expectations change [8]